Wenjun Liu1,1, Yongmei Xu1,1, Hongliang Guan1,1, Hongwei Meng2. 1. Department of Breast and Thyroid Surgery, Shanxian Central Hospital, Heze 274300, Shandong, China. 2. Department of Internal Medicine, Shanxian Central Hospital, Heze 274300, Shandong, China.
Abstract
BACKGROUND: Breast cancer remains the most invasive female malignancy worldwide. Functional role of microRNA-940 (miR-940) have been investigated in various cancer. The purpose of this study was to assess the serum miR-940 expression and its clinical significance in breast cancer. METHODS: Expression of miR-940 was measured by quantitative real-time polymerase chain reaction (qRT-PCR). The diagnostic value of miR-940 was analyzed with receiver operating characteristics (ROC) analysis. To explore the prognostic performance of miR-940, Kaplan-Meier survival assay and Cox regression analysis were performed. RESULTS: Downregulated miR-940 was detected in the breast cancer patients compared with the healthy controls (P< 0.001). The miR-940 expression was correlated with lymph node metastasis (P= 0.014) and TNM stage (P= 0.003). The area under the ROC curve (AUC) was 0.905, with sensitivity and specificity of 94.5% and 78.6%. From the survival curves, patients with low miR-940 expression had poor overall survival compare with those with high expression (log-rank P= 0.009). The Cox analysis indicated that miR-940 was an independent prognostic factor (HR = 2.645, 95% CI = 1.426-4.906 and P= 0.002). Decreased miR-940 expression was also been found in triple-negative breast cancer (TNBC) samples, and might predict poor prognosis in TNBC patients. CONCLUSIONS: Serum downregulated miR-940 may serve as a reliable diagnostic and prognostic biomarker in breast cancer patients.
BACKGROUND:Breast cancer remains the most invasive female malignancy worldwide. Functional role of microRNA-940 (miR-940) have been investigated in various cancer. The purpose of this study was to assess the serum miR-940 expression and its clinical significance in breast cancer. METHODS: Expression of miR-940 was measured by quantitative real-time polymerase chain reaction (qRT-PCR). The diagnostic value of miR-940 was analyzed with receiver operating characteristics (ROC) analysis. To explore the prognostic performance of miR-940, Kaplan-Meier survival assay and Cox regression analysis were performed. RESULTS: Downregulated miR-940 was detected in the breast cancerpatients compared with the healthy controls (P< 0.001). The miR-940 expression was correlated with lymph node metastasis (P= 0.014) and TNM stage (P= 0.003). The area under the ROC curve (AUC) was 0.905, with sensitivity and specificity of 94.5% and 78.6%. From the survival curves, patients with low miR-940 expression had poor overall survival compare with those with high expression (log-rank P= 0.009). The Cox analysis indicated that miR-940 was an independent prognostic factor (HR = 2.645, 95% CI = 1.426-4.906 and P= 0.002). Decreased miR-940 expression was also been found in triple-negative breast cancer (TNBC) samples, and might predict poor prognosis in TNBC patients. CONCLUSIONS: Serum downregulated miR-940 may serve as a reliable diagnostic and prognostic biomarker in breast cancerpatients.
Entities:
Keywords:
MiR-940; breast cancer; diagnosis; prognosis